{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '(e.g., bisphosphonates, denosumab) for bone metastases are also permitted per local', 'institutional standards. Other prescribed medications for non-neoplastic conditions are', 'allowed, as well as vitamins and nutritional supplements.', 'Concomitant prednisone (or equivalent) may be used at a dose of VI 10 mg/day. The use', 'of intermittent high-dose corticosteroid treatment to prevent or manage infusion reactions,', 'serosal effusions (see Section 6.1.8.1), or other non-cancer-related symptoms including', 'premedication for known hypersensitivity reactions to contrast for scans is allowed.', 'Routine prophylaxis with vaccines is permitted; however, vaccines used should not', 'contain live micro-organisms.', 'If the subject is taking chronic suppressive anti-infectives (antiviral, antifungal, or', 'antibacterial), appropriate investigation must be completed prior to randomization, and', 'documentation must exclude active infection. After exclusion of active infection,', 'otherwise eligible subjects should complete or continue suppressive anti-infectives as', 'prescribed.', 'If a subject requires palliative radiation during the study (e.g., symptomatic worsening of', 'a bone lesion) diagnostic imaging has to be performed to assess for radiographic', 'progression prior to radiation, and documentation of non-progressive status by', 'radiography will be captured in the eCRF. Any cancer-directed therapy a subject receives', 'due to disease improvement should be discussed with the TA MD in advance, if possible.', 'In the event of isolated CNS-only progression during study treatment, blinded', 'investigational product may be withheld while local treatment is administered', '(e.g., radiotherapy) in accordance with institutional practice. Blinded investigational', 'product may be restarted 1 week after the completion of local CNS disease-directed', 'therapy.', '40']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.2.3.3', 'Prohibited Therapy', 'Subjects may not receive other investigational drugs, immunosuppressive medications,', 'radiotherapy, or systemic anti-neoplastic therapy during the study, other than as allowed', 'in Section 5.2.3.2 and Section 5.2.3.2.1. Additionally, strong inhibitors of cytochrome', 'P450 3A4 (CYP3A4) should be avoided (refer to Table 1).', 'Table 1.', 'Examples of Strong CYP3A4 Inhibitors', 'Enzyme/Transporter', 'Strong Inhibitor Examples10', 'CYP3A4', 'boceprevir, clarithromycin, cobicistat, conivaptan,', 'danoprevir and ritonavir, diltiazem, elvitegravir', 'and ritonavir, idelalisib, indinavir and ritonavir,', 'itraconazole, ketoconazole, lopinavir and ritonavir,', 'nefazodone, nelfinavir paritaprevir and ritonavir', 'and (ombitasvir and/or dasabuvir), posaconazole,', 'ritonavir, saquinavir and ritonavir, telaprevir,', 'tipranavir and ritonavir, troleandomycin,', 'voriconazole', '(CYP) Cytochrome P450.', 'Note:', 'This is not an exhaustive list; so if in question, please refer to the appropriate product label.', '5.2.4', 'Contraception Recommendations', 'If female, subject must be either postmenopausal or permanently surgically sterile (refer', 'to inclusion criteria for definitions of both) OR a Woman of Childbearing Potential', '(WOCBP), practicing at least one of the following methods of birth control, on', 'randomization (or earlier) through at least 6 months after the last dose of blinded', 'investigational product.', 'Combined (estrogen and progestogen containing) hormonal contraception', '(oral, intravaginal, transdermal) associated with the inhibition of ovulation,', 'initiated at least 1 month prior to randomization.', 'Progestogen-only hormonal contraception (oral, injectable, implantable)', 'associated with inhibition of ovulation, initiated at least 1 month prior to', 'randomization.', '41']\n\n###\n\n", "completion": "END"}